logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Humoral Hypercalcemia Of Malignancy Disorder

    FiltersReset Filters
    5 results

    • methylprednisolone

      (METHYLPREDNISOLONE)
      Epic Pharma,LLC
      Usage: Methylprednisolone tablets are indicated for various conditions, including endocrine and rheumatic disorders, allergic states, dermatologic diseases, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and acute nervous system disorders, providing symptomatic relief or maintenance therapy.

    • methylprednisolone acetate

      (Methylprednisolone acetate)
      Amneal Pharmaceuticals LLC
      Usage: Methylprednisolone acetate injectable suspension is indicated for intramuscular, intra-articular, or intralesional administration to treat severe allergic conditions, dermatologic diseases, endocrine disorders, hematologic disorders, and various respiratory and rheumatic diseases, as well as for palliative care in neoplastic diseases and specific ophthalmic and renal conditions.

    • methylprednisolone sodium succinate

      (Methylprednisolone)
      Amneal Pharmaceuticals LLC
      Usage: Methylprednisolone sodium succinate is indicated for intravenous or intramuscular administration in severe allergic conditions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neurological conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders, especially when oral therapy is not feasible.

    • rayos

      (prednisone)
      Horizon Therapeutics USA, Inc.
      Usage: RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

    • xgeva

      (denosumab)
      Amgen Inc
      Usage: Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors. It treats giant cell tumor of bone that is unresectable or poses severe surgical risks, and it addresses hypercalcemia of malignancy that is refractory to bisphosphonate therapy.